Biopharmaceutical Company Focused On The Development And Commercialization Of
Novel Therapeutics To Treat Chronic Liver Diseases."
Intercept Pharmaceuticals (ICPT)
is a biopharmaceutical company focused on the development and
commercialization of novel therapeutics to treat orphan and more prevalent
liver diseases utilizing its expertise in bile acid chemistry.
The company's lead product
candidate, obeticholic acid, is a bile acid analog and first-in-class
agonist of the farnesoid X receptor. OCA is being developed for a variety of
chronic liver diseases including NASH, primary biliary cirrhosis, portal
hypertension and bile acid diarrhea.
OCA has received orphan drug
designation in both the United States and Europe for the treatment of PBC.
Intercept owns worldwide rights to OCA outside of Japan and China.
that the FLINT trial of obeticholic acid (OCA) for the treatment of
nonalcoholic steatohepatitis (NASH) has been stopped early for efficacy
based on a planned interim analysis showing that the primary endpoint of
the trial has been met.
early stopping of FLINT due to OCA meeting the primary endpoint with
such high significance is a major milestone," said Mark Pruzanski,
M.D., Chief Executive Officer of Intercept. "NASH has grown to
epidemic proportions worldwide, having become a leading cause of
cirrhosis and liver failure."
As of September 30,
2013, Intercept's cash, cash equivalents and investment securities
available for sale totaled approximately $156.8 million, compared
to $110.2 million at December 31, 2012.
News and Press Releases
Announces NASH Primary Endpoint Met: FLINT Trial Stopped Early for Efficacy
Based on Highly Statistically Significant Improvement in Liver Histology
Pharmaceuticals to Provide 2013 Update on Clinical Programs for Obeticholic
Acid on January 9
Pharmaceuticals Reports Third Quarter 2013 Financial Results
For the latest Quote
and News on ICPT Click
Pruzanski, M.D. - Chief Executive Officer and President
Mark Pruzanski, M.D. is a
co-founder of the company and has served as chief executive officer and
president, and has been a member of the board of directors, since inception
He has over 15 years of
experience in life sciences company management, venture capital and
strategic consulting. Dr. Pruzanski was previously a venture partner at
Apple Tree Partners, an early stage life sciences venture capital firm he
co-founded in 1999.
Prior to that, he was an
entrepreneur-in-residence at Oak Investment Partners. Dr. Pruzanski received
his M.D. from McMaster University in Ontario, a M.A. degree in International
Affairs from the Johns Hopkins University School of Advanced International
Studies in Bologna, Italy and Washington, D.C., and a bachelors degree from
McGill University in Montreal, Quebec.
He currently also serves on the
boards of the Emerging Company Section of the Biotechnology Industry
Association and the Foundation for the Defense of Democracies, a think tank
in Washington, D.C.
Dr. Pruzanski is a co-author of
a number of scientific publications and an inventor of several patents
relating to our product candidates and scientific discoveries.
Shapiro, M.D. - Chief Medical Officer and Excutive Vice-President,
David Shapiro, M.D. has served
as chief medical officer and executive vice president, development since
2008. He has over 25 years of clinical development experience in the
Dr. Shapiro founded a consulting
company, Integrated Quality Resources, that focused on development stage
biopharmaceutical companies and was active in this role from 2005 to 2008.
From 2000 to 2005, Dr. Shapiro was executive vice president, medical affairs
and chief medical officer of Idun Pharmaceuticals, Inc., prior to its
acquisition by Pfizer. From 1995 to 1998, he was president of the Scripps
Medical Research Center at Scripps Clinic. He also served as vice president,
clinical research at Gensia and as director and group leader, hypertension
clinical research at Merck Research Laboratories from 1985 to 1990.
Dr. Shapiro has authored more
than 20 peer-reviewed publications and organized and chaired several
conferences aimed at improving product development. He received his medical
degree from Dundee University & Medical School, and undertook his
postgraduate medical training in the university affiliated hospitals in
Oxford, United Kingdom and the University of Vermont.
Dr. Shapiro served on the board
of directors of Altair Therapeutics and served for two terms on the
Executive Committee of the Board of the American Academy of Pharmaceutical
Physicians. He is an elected Fellow of both the Royal College of Physicians
of London and the Faculty of Pharmaceutical Physicians of the United
Duncan - Chief Financial Officer
Barbara Duncan has served as
chief financial officer and secretary since May 2009 and as treasurer since
2010. She has over 14 years experience in the life sciences industry. From
2001 through April 2009, Ms. Duncan served as chief financial officer and
then chief executive officer at DOV Pharmaceutical, Inc., or DOV, a
biopharmaceutical company focused on central nervous system disorders, which
was sold to Euthymics Bioscience, Inc. in 2010.
Prior to joining DOV, Ms. Duncan
served as a vice president of Lehman Brothers Inc. in its corporate finance
division from August 1998 to August 2001, where she provided financial
advisory services primarily to companies in the life sciences and general
industrial industries. From September 1994 to August 1998, Ms. Duncan was an
associate and director at SBC Warburg Dillon Read, Inc. in its corporate
finance group, where she focused primarily on structuring mergers,
divestitures and financings for companies in the life sciences and general
industrial industries. She also worked for PepsiCo, Inc. from 1989 to 1992
in its international audit division, and was a certified public accountant
in the audit division of Deloitte & Touche LLP from 1986 to 1989.
Ms. Duncan received her B.S.
from Louisiana State University in 1985 and her M.B.A. from the Wharton
School, University of Pennsylvania, in 1994. She previously served as a
director of DOV and currently serves on the board of directors of Edgemont
Pharmaceuticals, LLC, a privately held, specialty pharmaceutical company
with a primary focus in the field of neuroscience.
ICPT filings with the SEC can be
18 Desbrosses Street
New York, NY 10013
feature stock reports are intended to be stock ideas, not recommendations.
Please do your own research before investing. It is crucial that you at
least look at current SEC filings and read the latest press releases. Information contained in this report was extracted from current documents
filed with the SEC, the company website and other publicly available
sources deemed reliable. For more information see our disclaimer section, a
link of which can be found on our website. This document contains
forward-looking statements, particularly as related to the business plans of
the Company, within the meaning of Section 27A of the Securities Act of 1933
and Sections 21E of the Securities Exchange Act of 1934, and is subject to
the safe harbor created by these sections. Actual results may differ
materially from the Company's expectations and estimates. The information
provided in this report is not intended for distribution to, or use by, any
person or entity in any jurisdiction or country where such distribution or
use would be contrary to law or regulation or which would subject us to any
registration requirement within such jurisdiction or country.
SmallCapReview. All rights reserved. SCR is not a
Registered Broker/Dealer or Financial Advisor. All materials presented on our website and individual reports
released to the public through this website, e-mail or any other means of
transmission are not to be regarded as investment advice and are only
for informative purposes. Before making a purchase or sale of any securities featured
on our web site or mentioned in our reports, we strongly encourage and
recommend consultation with a registered securities representative. This
is not to be construed as a solicitation or recommendation to buy or sell
with any stock, companies we select to profile involve a
degree of investment risk and volatility, particularly small-caps. All investors are cautioned that they may lose all or a portion of
their investment if they decide to make a purchase in any of our profiled
companies. Past performance of our profiled stocks is not indicative of
future results. The profile and opinions expressed herein are expressed
as of the date the profile is posted on site and are subject to change
without notice. No investor should assume that reliance on the views,
opinions or recommendations contained herein will produce profitable results.
SmallCapReview may hold positions in securities mentioned herein, and may
make purchases or sales in such securities featured on our website or within
In order to
be in full compliance with the Securities Act of 1933, Section 17(b), SCR will disclose in it's disclaimer, what, if any
compensation was received for our efforts in researching, presenting
and disseminating this information to our subscriber database and featuring
the report on the SmallCapReview website. SmallCapReview has
not been compensated for its efforts with regards to Intercept
encourage our readers to invest carefully and read the investor information
available at the web sites of the Securities and Exchange Commission (SEC)
and/or the National Association of Securities Dealers (NASD) at: http://www.nasd.com
. Readers can review all public filings by companies at the SEC's EDGAR
page. The NASD has published information on how to invest carefully at its